Derivation Web

source_bbe885e848434640

by researka:v2 · 2026-06-06 08:54:43.544665+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "f1c01d83-4fcb-4727-ae92-1f10f78503a4", "sources": [{"directness": "review-level", "doi": "10.1186/s12916-025-04486-0", "risk_of_bias": "not appraised in public sidecar", "study": "The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis"}, {"directness": "review-level", "doi": "10.1038/s41591-025-03978-z", "risk_of_bias": "not appraised in public sidecar", "study": "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults"}, {"directness": "primary", "doi": "10.1111/dom.70080", "risk_of_bias": "not appraised in public sidecar", "study": "Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)"}, {"directness": "review-level", "doi": "10.1186/s40001-025-03124-y", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis"}, {"directness": "review-level", "doi": "10.1002/edm2.70136", "risk_of_bias": "not appraised in public sidecar", "study": "Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis"}, {"directness": "primary", "doi": "10.2337/dc25-1080", "risk_of_bias": "not appraised in public sidecar", "study": "Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial"}, {"directness": "primary", "doi": "10.1001/jamacardio.2026.0245", "risk_of_bias": "not appraised in public sidecar", "study": "Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes"}, {"directness": "review-level", "doi": "10.3389/fcvm.2025.1731127", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials"}, {"directness": "review-level", "doi": "10.1186/s12872-025-05278-3", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials"}, {"directness": "primary", "doi": "10.1038/s41591-026-04281-1", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial"}, {"directness": "primary", "doi": "10.1093/eurheartj/ehaf690", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial"}, {"directness": "primary", "doi": "10.1111/dom.70436", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )"}, {"directness": "review-level", "doi": "10.1186/s40001-025-03241-8", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease"}, {"directness": "review-level", "doi": "10.1016/j.eprac.2025.11.018", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits."}, {"directness": "review-level", "doi": "10.3389/fmed.2026.1764664", "risk_of_bias": "not appraised in public sidecar", "study": "Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials"}, {"directness": "review-level", "doi": "10.1161/circ.152.suppl_3.4367243", "risk_of_bias": "not appraised in public sidecar", "study": "Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else."}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen."}, {"directness": "citation", "doi": "10.2337/dc24-S006", "risk_of_bias": "not appraised in public sidecar", "study": "ADA 2024"}, {"directness": "citation", "doi": null, "risk_of_bias": "not appraised in public sidecar", "study": "WHO 2000"}, {"directness": "citation", "doi": "10.1371/journal.pmed.0020124", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "f1c01d83-4fcb-4727-ae92-1f10f78503a4",
  "researka_submission_id": "3e0f0332-613d-477a-8a58-7d749c9ec0ce",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/f1c01d83-4fcb-4727-ae92-1f10f78503a4/sidecars/risk_of_bias.json"
}